Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
1.44 ^USD	0.00%		+23.08%	+111.76%

Apr. 18	Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	MT
Apr. 18	Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	DJ

Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 08:11 am EDT

Imunon, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 19.51 million compared to USD 35.9 million a year ago. Basic loss per share from continuing operations was USD 2.16 compared to USD 5.03 a year ago.

Latest news about Imunon, Inc.

Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	Apr. 18	MT
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	Apr. 18	DJ
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101	Apr. 18	CI
HC Wainwright Adjust Price Target on Imunon to $13 From $12, Keeps Buy Rating	Apr. 01	MT
Top Midday Gainers	Mar. 28	MT
Transcript : Imunon, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101	Mar. 13	CI
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff	Mar. 13	MT
Imunon, Inc. Announces Executive Changes	Mar. 12	CI
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024	Mar. 12	CI
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer	Dec. 11	CI
Transcript : Imunon, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer	Nov. 14	CI
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer	23-10-18	CI
Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board	23-10-06	CI
Transcript : Imunon, Inc. - Special Call	23-09-14
Imunon Strikes Deal For Preclinical Studies in Vaccines Against Lassa Virus	23-08-24	MT
Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board	23-08-14	CI
Transcript : Imunon, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv	23-08-07	CI
Imunon Opening New Manufacturing Facility in Alabama to Support Production of Vaccine Formulation Components	23-06-27	MT

Chart Imunon, Inc.

Duration

Period

More charts

Company Profile

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.44 USD

Average target price

12 USD

Spread / Average Target

+733.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMUNON, INC.	+111.76%	13.54M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs